Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Wednesday. The brokerage issued a hold rating on the stock.

EKSO has been the subject of several other reports. Lake Street Capital reduced their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. HC Wainwright dropped their price target on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Stock Performance

Shares of EKSO stock opened at $0.70 on Wednesday. The stock has a fifty day moving average price of $0.95 and a 200 day moving average price of $1.07. The stock has a market cap of $15.29 million, a PE ratio of -1.02 and a beta of 1.47. Ekso Bionics has a 1 year low of $0.66 and a 1 year high of $3.13. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The firm had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same period in the prior year, the firm posted ($0.24) earnings per share. Sell-side analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.